The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease

References

• Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 inhibition in Behçet’s disease. Isr Med Assoc J. 2016;18(3–4):171–176.
   PubMed Web of Science ®Google Scholar
• Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(5):S6–12.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013;39(2):245–261. doi:10.1016/j.rdc.2013.02.010.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Orlando I, et al. Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study. Intern Emerg Med. 2017;12:947–955. doi:10.1007/s11739-017-1691-z.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Leccese P, Christensen R, et al. A systematic literature review on the treatment of major organ involvement of Behçet’s syndrome informing the EULAR recommendations for the management of Behçet’s syndrome. Clin Exp Rheumatol. 2016;34:S175.
   Web of Science ®Google Scholar
• Vitale A, Rigante D, Lopalco G, et al. New therapeutic solutions for Behçet’s syndrome. Expert Opin Investig Drugs. 2016;25(7):827–840. doi:10.1080/13543784.2016.1181751.
   PubMed Web of Science ®Google Scholar
• Pagnini I, Bondi T, Simonini G, Giani T, Marino A, Cimaz R. Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology (Oxford). 2015;54(7):1327–1328. doi:10.1093/rheumatology/kev197.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L. Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol. 2014;32(4):S171.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology (Basel, Switzerland). 2014;228(3):211–214. doi:10.1159/000358125.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301. doi:10.1007/s10067-013-2443-8.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol. 2013;31(3):152–153.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589–1591. doi:10.1136/annrheumdis-2012-201383.
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149(4):284–286.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Tosi GM, et al. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2016. doi:10.1007/s10067-016-3527-z. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:191–197. doi:10.1007/s10067-016-3506-4.
   PubMed Web of Science ®Google Scholar
• Vitale A, Insalaco A, Sfriso P, et al. A Snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380. doi:10.3389/fphar.2016.00323.
   PubMed Web of Science ®Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566. doi:10.1136/annrheumdis-2011-155143.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Kadayifcilar S, Khairallah M, et al. Safety and efficacy of gevokizumab in patients with Behçet’s Disease Uveitis: results of an Exploratory Phase 2 Study. Ocul Immunol Inflamm. 2017;25:62–70. doi:10.3109/09273948.2015.1092558.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–1286. doi:10.1007/s10067-015-3004-0.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, Franceschini R, Cantarini L. Interleukin-1 blockade in neuro-Behçet’s disease: a case-based reflection. Int J Rheum Dis. 2015. [ Epub ahead of print]. doi:10.1111/1756-185X.12680.
   Web of Science ®Google Scholar
• Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease. Lancet. 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Abdollahi BS, Chams-Davatchi C, et al. Validation of the revised International Criteria for Behcet’s disease (ICBD) in Iran. Clin Rheumatol. 2015;34(2):315–320. doi:10.1007/s10067-013-2411-3.
   PubMed Web of Science ®Google Scholar
• Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol. 2007;26(8):1263–1267. doi:10.1007/s10067-006-0484-y.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils and perspectives. Mediators Inflamm. 2015;2015:194864. doi:10.1155/2015/125380.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Lucherini OM, et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm. 2013;2013:93984. doi:10.1155/2013/939847.
   Google Scholar
• Cantarini L, Lucherini OM, Frediani B, et al. Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol. 2011;24(4):827–836. doi:10.1177/039463201102400402.
   PubMed Web of Science ®Google Scholar
• Rigante D, Ansuini V, Caldarelli M, Bertoni B, La Torraca I, Stabile A. Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst. 2006;22(4):334–337. doi:10.1007/s00381-006-1280-3.
   PubMed Web of Science ®Google Scholar
• Rigante D. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. Expert Rev Clin Immunol. 2017;13(6):571–597. doi:10.1080/1744666X.2017.1280396.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Galeotti C. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2015;11(10):1083–1092. doi:10.1586/1744666X.2015.1077702.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19(9):1833–1838. doi:10.1097/MIB.0b013e31828f19c9.
   PubMed Web of Science ®Google Scholar
• Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984;43(6):783–789.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Long-term efficacy and safety of anakinra in a patient with Behçet’s disease and concomitant tuberculosis infection. Int J Dermatol. 2017;56(2):218–220. doi:10.1111/ijd.13337.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gül A. Use of Gevokizumab in Patients with Behçet’s disease uveitis: an International, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018 Jan 25:1–11: doi:10.1080/09273948.2017.1421233. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ. Cutting Edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. J Immunol. 2016;196(2):543–546. doi:10.4049/jimmunol.1502080.
   PubMed Web of Science ®Google Scholar
• Yazıcı H, Seyahi E. Behçet syndrome: the vascular cluster. Turk J Med Sci. 2016;46(5):1277–1280. doi:10.3906/sag-1605-28.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Lucherini OM, Lopalco A, et al. Cytokine signatures in mucocutaneous and ocular Behçet’s disease. Front Immunol. 2017;8:200. doi:10.3389/fimmu.2017.00200.
   PubMed Web of Science ®Google Scholar